StockData
Elicio Therapeutics, Inc. logo

Elicio Therapeutics, Inc. (ELTX) stock

ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$1.59+0.16 (+11.19%)

Close on Nov 18, 2026Market cap $41.79MP/E –Yield –

Elicio Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Elicio Therapeutics's revenue for the twelve months ending Mar 31, 2023 was $653.00K, down 97.8% year over year. For fiscal 2022 it was $2.30M, down 91.9% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2022Dec 31, 2022$2.30M-91.9%
FY2021Dec 31, 2021$28.31M+883.1%
FY2020Dec 31, 2020$2.88M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2023Mar 31, 2023$0-100.0%
Q4 FY2022Dec 31, 2022$0-100.0%
Q3 FY2022Sep 30, 2022$0-100.0%
Q2 FY2022Jun 30, 2022$653.00K+20.9%
Q1 FY2022Mar 31, 2022$1.65M+344.2%
Q4 FY2021Dec 31, 2021$25.94M+5551.6%
Q3 FY2021Sep 30, 2021$1.46M+76.5%
Q2 FY2021Jun 30, 2021$540.00K-25.9%
Q1 FY2021Mar 31, 2021$371.00K-57.1%
Q4 FY2020Dec 31, 2020$459.00K–
Q3 FY2020Sep 30, 2020$827.00K–
Q2 FY2020Jun 30, 2020$729.00K–
Q1 FY2020Mar 31, 2020$865.00K–

More Elicio Therapeutics figures

See a number that looks wrong?